MA55201A - Inhibiteurs de la voie jak1 pour le traitement d'un dysfonctionnement chronique de l'allogreffe pulmonaire - Google Patents
Inhibiteurs de la voie jak1 pour le traitement d'un dysfonctionnement chronique de l'allogreffe pulmonaireInfo
- Publication number
- MA55201A MA55201A MA055201A MA55201A MA55201A MA 55201 A MA55201 A MA 55201A MA 055201 A MA055201 A MA 055201A MA 55201 A MA55201 A MA 55201A MA 55201 A MA55201 A MA 55201A
- Authority
- MA
- Morocco
- Prior art keywords
- treatment
- pathway inhibitors
- chronic lung
- lung allograft
- allograft dysfunction
- Prior art date
Links
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 title 1
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 title 1
- 230000001684 chronic effect Effects 0.000 title 1
- 230000004064 dysfunction Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 210000004072 lung Anatomy 0.000 title 1
- 230000037361 pathway Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962814085P | 2019-03-05 | 2019-03-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA55201A true MA55201A (fr) | 2022-01-12 |
Family
ID=69941525
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA055201A MA55201A (fr) | 2019-03-05 | 2020-03-05 | Inhibiteurs de la voie jak1 pour le traitement d'un dysfonctionnement chronique de l'allogreffe pulmonaire |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11406640B2 (fr) |
| EP (2) | EP3934651A1 (fr) |
| JP (2) | JP2022524997A (fr) |
| KR (1) | KR20210137087A (fr) |
| CN (1) | CN114007621A (fr) |
| AU (1) | AU2020232757B2 (fr) |
| CA (1) | CA3132371A1 (fr) |
| EA (1) | EA202192426A1 (fr) |
| IL (1) | IL285999B2 (fr) |
| MA (1) | MA55201A (fr) |
| MX (2) | MX2021010545A (fr) |
| PH (1) | PH12021552130A1 (fr) |
| SG (1) | SG11202109563WA (fr) |
| WO (1) | WO2020181034A1 (fr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10836763B2 (en) | 2018-09-04 | 2020-11-17 | Theravance Biopharma R&D Ip, Llc | 5 to 7 membered heterocyclic amides as JAK inhibitors |
| KR102826491B1 (ko) | 2018-09-04 | 2025-06-27 | 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 | Jak 억제제로서 디메틸 아미노 아제티딘 아마이드 |
| JP2022506111A (ja) | 2018-10-29 | 2022-01-17 | セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー | Ｊａｋ阻害剤としての２－アザビシクロヘキサン化合物 |
| IL282643B2 (en) | 2018-10-31 | 2025-08-01 | Incyte Corp | A selective jak1 inhibitor for use in a method of treating hematological disease |
| IL285999B2 (en) * | 2019-03-05 | 2026-01-01 | Incyte Corp | JAK1 inhibitor pathway for the treatment of chronic lung allograft dysfunction |
| US11992490B2 (en) | 2019-10-16 | 2024-05-28 | Incyte Corporation | Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP) |
| TW202144343A (zh) | 2020-03-02 | 2021-12-01 | 美商施萬生物製藥研發 Ip有限責任公司 | Jak抑制劑化合物之結晶水合物 |
| MX2023008141A (es) * | 2021-01-11 | 2023-10-20 | Incyte Corp | Terapia combinada que comprende el inhibidor de la vía de proteínas tirosina cinasas de janus cinasas (jak) y el inhibidor de la proteína cinasa asociada a rho (rock). |
| TW202317550A (zh) | 2021-06-25 | 2023-05-01 | 美商施萬生物製藥研發 Ip有限責任公司 | 作為jak抑制劑之咪唑吲唑化合物 |
| KR20230053831A (ko) | 2021-10-15 | 2023-04-24 | 주식회사 엘지에너지솔루션 | 용접봉 체결 방법 및 이에 의해 용접봉이 수직으로 체결된 용접 장치 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60105023T2 (de) | 2000-06-28 | 2005-08-18 | Smithkline Beecham P.L.C., Brentford | Nassvermahlungsverfahren |
| TWI630207B (zh) | 2005-12-13 | 2018-07-21 | 英塞特控股公司 | 作為傑納斯激酶（ＪＡＮＵＳ ＫＩＮＡＳＥ）抑制劑之經雜芳基取代之吡咯并〔２，３-ｂ〕吡啶及吡咯并〔２，３-ｂ〕嘧啶 |
| WO2007103970A2 (fr) | 2006-03-07 | 2007-09-13 | Endacea, Inc. | Compositions et procédés de traitement de troubles respiratoires |
| US8058227B2 (en) | 2006-10-03 | 2011-11-15 | Medical University Of South Carolina | Method of treating fibrosis in a subject in need thereof comprising administering a composition comprising a CSD |
| EP3070090B1 (fr) | 2007-06-13 | 2018-12-12 | Incyte Holdings Corporation | Utilisation des sels de l'inhibiteur de janus kinase (r)-3-(4- (7h-pyrrolo [2,3-d] pyrimidin-4-yl)-1h-pyrazol-1-yl) -3-cyclopentylpropanenitrile |
| TWI519298B (zh) | 2008-04-17 | 2016-02-01 | 賽諾菲 安萬特公司 | 決奈達隆（ｄｒｏｎｅｄａｒｏｎｅ）於製備用於預防心血管疾病住院或死亡之藥劑之用途 |
| AR076794A1 (es) | 2009-05-22 | 2011-07-06 | Incyte Corp | Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo [2,3-d]pirimidinas y pirrol-3-il-pirrolo [2,3-d ]pirimidinas como inhibidores de la quinasa janus y composiciones farmaceuticas que los contienen |
| AR078012A1 (es) | 2009-09-01 | 2011-10-05 | Incyte Corp | Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus |
| ME02800B (fr) | 2009-12-01 | 2018-01-20 | Abbvie Inc | Composés tricycliques innovants |
| EP3050882B1 (fr) | 2010-03-10 | 2018-01-31 | Incyte Holdings Corporation | Dérivés de pipéridin -4-yl azétidine utilisés en tant qu'inhibiteurs de jak1 |
| BR112013008240A2 (pt) | 2010-10-08 | 2017-12-12 | Abbvie Inc | compostos de furo [3-2-d] pirimidina |
| CN103415515B (zh) | 2010-11-19 | 2015-08-26 | 因塞特公司 | 作为jak抑制剂的环丁基取代的吡咯并吡啶和吡咯并嘧啶衍生物 |
| US9034884B2 (en) | 2010-11-19 | 2015-05-19 | Incyte Corporation | Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors |
| PE20140832A1 (es) | 2011-06-20 | 2014-07-14 | Incyte Corp | Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak |
| TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物 |
| UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
| TW201406761A (zh) | 2012-05-18 | 2014-02-16 | Incyte Corp | 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物 |
| ES2867048T3 (es) | 2012-06-15 | 2021-10-20 | Concert Pharmaceuticals Inc | Derivados deuterados de ruxolitinib |
| BR112015003153A2 (pt) | 2012-08-17 | 2017-07-04 | Concert Pharmaceuticals Inc | baricitinib deuterado |
| AU2013337824B2 (en) | 2012-11-01 | 2018-03-08 | Incyte Holdings Corporation | Tricyclic fused thiophene derivatives as JAK inhibitors |
| CN105189509B (zh) | 2013-03-06 | 2017-12-19 | 因赛特公司 | 用于制备jak抑制剂的方法及中间体 |
| SMT202100040T1 (it) | 2013-05-17 | 2021-03-15 | Incyte Corp | Derivati di bipirazolo come inibitori di jak |
| SG10201912203XA (en) * | 2013-08-07 | 2020-02-27 | Incyte Corp | Sustained release dosage forms for a jak1 inhibitor |
| CA2926361A1 (fr) * | 2013-10-24 | 2015-04-30 | Abbvie Inc. | Inhibiteur selectif de jak1 et ses utilisations |
| CA2940659C (fr) | 2014-02-28 | 2023-01-03 | Incyte Corporation | Inhibiteurs des jak1 pour le traitement de syndromes myelodysplasiques |
| JP2017514832A (ja) | 2014-04-30 | 2017-06-08 | インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ | Ｊａｋ１抑制剤を調製する方法及びその新しい形態 |
| WO2015184305A1 (fr) | 2014-05-30 | 2015-12-03 | Incyte Corporation | Traitement de la leucémie neutrophile chronique (cnl) et de la leucémie myéloïde chronique atypique (acml) par des inhibiteurs de jak1 |
| KR20180073687A (ko) | 2015-11-03 | 2018-07-02 | 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 | 호흡기 질환의 치료를 위한 jak 키나제 저해제 화합물 |
| CN105294699B (zh) * | 2015-12-04 | 2019-06-11 | 上海勋和医药科技有限公司 | 巴瑞替尼的制备方法 |
| CN108366994B (zh) * | 2016-10-03 | 2021-10-01 | 杭州高光制药有限公司 | 新型Jak1选择性抑制剂及其用途 |
| EP3327020A1 (fr) * | 2016-11-29 | 2018-05-30 | Sandoz Ag | Sels de citrate d'un inhibiteur de kinase de janus (jak) |
| EA037748B1 (ru) | 2017-03-09 | 2021-05-18 | ТЕРЕВАНС БАЙОФАРМА Ар энд Ди АйПи, ЭлЭлСи | Конденсированные имидазо-пиперидиновые ингибиторы jak |
| AR111495A1 (es) | 2017-05-01 | 2019-07-17 | Theravance Biopharma R&D Ip Llc | Compuestos de imidazo-piperidina fusionada como inhibidores de jak |
| SG11201909019SA (en) | 2017-05-01 | 2019-10-30 | Theravance Biopharma R&D Ip Llc | Methods of treatment using a jak inhibitor compound |
| EP3746429B1 (fr) | 2018-01-30 | 2022-03-09 | Incyte Corporation | Procédés de préparation de (1-(3-fluoro-2-(trifluorométhyl)isonicotinyl)pipéridine-4-one) |
| KR102830476B1 (ko) | 2018-02-16 | 2025-07-08 | 인사이트 코포레이션 | 사이토카인-관련 장애의 치료를 위한 jak1 경로 억제제 |
| PT3773593T (pt) | 2018-03-30 | 2024-06-25 | Incyte Corp | Tratamento da hidradenite supurativa com inibidores de jak |
| SG11202010092XA (en) | 2018-04-13 | 2020-11-27 | Incyte Corp | Biomarkers for graft-versus-host disease |
| IL282643B2 (en) | 2018-10-31 | 2025-08-01 | Incyte Corp | A selective jak1 inhibitor for use in a method of treating hematological disease |
| PH12021551455A1 (en) | 2018-12-19 | 2022-04-18 | Incyte Corp | Jak1 pathway inhibitors for the treatment of gastrointestinal disease |
| IL285999B2 (en) | 2019-03-05 | 2026-01-01 | Incyte Corp | JAK1 inhibitor pathway for the treatment of chronic lung allograft dysfunction |
| US11624751B2 (en) | 2019-03-19 | 2023-04-11 | Incyte Corporation | Biomarkers for vitiligo |
-
2020
- 2020-03-05 IL IL285999A patent/IL285999B2/en unknown
- 2020-03-05 MA MA055201A patent/MA55201A/fr unknown
- 2020-03-05 EP EP20713496.6A patent/EP3934651A1/fr active Pending
- 2020-03-05 WO PCT/US2020/021088 patent/WO2020181034A1/fr not_active Ceased
- 2020-03-05 EA EA202192426A patent/EA202192426A1/ru unknown
- 2020-03-05 SG SG11202109563WA patent/SG11202109563WA/en unknown
- 2020-03-05 KR KR1020217031644A patent/KR20210137087A/ko active Pending
- 2020-03-05 CN CN202080024215.0A patent/CN114007621A/zh active Pending
- 2020-03-05 EP EP25213638.7A patent/EP4691567A2/fr active Pending
- 2020-03-05 CA CA3132371A patent/CA3132371A1/fr active Pending
- 2020-03-05 AU AU2020232757A patent/AU2020232757B2/en active Active
- 2020-03-05 MX MX2021010545A patent/MX2021010545A/es unknown
- 2020-03-05 PH PH1/2021/552130A patent/PH12021552130A1/en unknown
- 2020-03-05 JP JP2021552624A patent/JP2022524997A/ja active Pending
- 2020-03-05 US US16/810,045 patent/US11406640B2/en active Active
-
2021
- 2021-09-02 MX MX2024007081A patent/MX2024007081A/es unknown
-
2022
- 2022-06-30 US US17/854,443 patent/US11896595B2/en active Active
-
2025
- 2025-02-21 JP JP2025026650A patent/JP2025087734A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025087734A (ja) | 2025-06-10 |
| MX2021010545A (es) | 2021-11-17 |
| EP3934651A1 (fr) | 2022-01-12 |
| US20220331325A1 (en) | 2022-10-20 |
| IL285999A (en) | 2021-10-31 |
| MX2024007081A (es) | 2024-06-21 |
| CA3132371A1 (fr) | 2020-09-10 |
| AU2020232757A1 (en) | 2021-10-07 |
| WO2020181034A1 (fr) | 2020-09-10 |
| JP2022524997A (ja) | 2022-05-11 |
| IL285999B2 (en) | 2026-01-01 |
| US11406640B2 (en) | 2022-08-09 |
| KR20210137087A (ko) | 2021-11-17 |
| AU2020232757B2 (en) | 2025-09-11 |
| CN114007621A (zh) | 2022-02-01 |
| US20200281931A1 (en) | 2020-09-10 |
| SG11202109563WA (en) | 2021-09-29 |
| PH12021552130A1 (en) | 2022-08-31 |
| IL285999B1 (en) | 2025-09-01 |
| EA202192426A1 (ru) | 2021-11-15 |
| EP4691567A2 (fr) | 2026-02-11 |
| US11896595B2 (en) | 2024-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA55201A (fr) | Inhibiteurs de la voie jak1 pour le traitement d'un dysfonctionnement chronique de l'allogreffe pulmonaire | |
| MA51829A (fr) | Inhibiteurs de la voie jak1 pour le traitement de troubles liés aux cytokines | |
| MA54544A (fr) | Inhibiteurs de la voie jak1 pour le traitement d'une maladie gastro-intestinale | |
| MA56508A (fr) | Inhibiteur d'egfr pour le traitement du cancer | |
| EP3600281A4 (fr) | Traitement d'association pour le traitement ou la prévention de tumeurs | |
| EP3765611A4 (fr) | Oligonucléotides ciblant la pcsk9 pour le traitement de l'hypercholestérolémie et d'états apparentés | |
| EP3706753A4 (fr) | Inhibiteurs de la voie de l'adénosine pour le traitement du cancer | |
| EP3737361A4 (fr) | Inhibiteurs de la dihydrocéramide désaturase pour le traitement d'une maladie | |
| EP3630287A4 (fr) | Inhibiteurs de parp radiomarqués et fluorescents pour l'imagerie et la radiothérapie | |
| EP3700516A4 (fr) | Inhibiteurs de l'induction de dux4 pour la régulation de la fonction musculaire | |
| EP3434291A4 (fr) | Composition pour le traitement d'un disque intervertébral | |
| EP3969111A4 (fr) | Formulations inhalables pour l'inhibition de kinases | |
| EP3541379A4 (fr) | Compositions pour le traitement de l'hypertension | |
| EP3877402A4 (fr) | Traitement combiné pour l'hypertension résistante | |
| EP3863671A4 (fr) | Anticorps monoclonal pour le traitement de la leucémie lymphoblastique aiguë | |
| EP3898991A4 (fr) | Administration périnéale de résinifératoxine pour le traitement de la douleur maladaptative | |
| EP3687537A4 (fr) | Nouveaux inhibiteurs d'usp7 pour le traitement du myélome multiple | |
| EP3810091A4 (fr) | Méthodes et compositions pour le traitement de l'hypertension pulmonaire | |
| EP3976612A4 (fr) | Nouveaux composés pour l'inhibition de la janus kinase 1 | |
| MA54522A (fr) | Composition pharmaceutique pour le traitement de l'hypertension artérielle pulmonaire | |
| MA55486A (fr) | Inhibiteurs de la tyrosine kinase fgfr pour le traitement du carcinome urothélial | |
| MA55490A (fr) | Mutéine de lipocaline pour le traitement de l'asthme | |
| EP3931178A4 (fr) | Composés pour la prévention et le traitement d'un dysfonctionnement cognitif post-opératoire | |
| EP4073060A4 (fr) | Inhibiteurs de l'histone déméthylase spécifique de la lysine pour le traitement de néoplasmes myéloprolifératifs | |
| EP3848084A4 (fr) | Valve programmable pour le traitement de l'hydrocéphalie |